Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Vasopressin Patent Expiration

Vasopressin is Used for increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. It was first introduced by Endo Operations Ltd in its drug Vasostrict on Apr 17, 2014. Other drugs containing Vasopressin are Vasopressin, Vasopressin In Sodium Chloride 0.9%. 12 different companies have introduced drugs containing Vasopressin.


Vasopressin Patents

Given below is the list of patents protecting Vasopressin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vasostrict US10010575 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US12186362 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9375478 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9687526 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9744209 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9744239 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9750785 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9919026 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9925233 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9925234 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9937223 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9962422 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9968649 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9974827 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations
Vasostrict US9981006 Vasopressin formulations for use in treatment of hypotension Jan 30, 2035 Endo Operations



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vasopressin's patents.

Given below is the list recent legal activities going on the following patents of Vasopressin.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 10 Nov, 2023 US9375478
Email Notification
Critical
 28 May, 2022 US9925234
Change in Power of Attorney (May Include Associate POA)
Critical
 27 May, 2022 US9925234
Correspondence Address Change
Critical
 26 May, 2022 US9925234
Payment of Maintenance Fee, 4th Year, Large Entity 09 Dec, 2021 US10010575
Payment of Maintenance Fee, 4th Year, Large Entity 14 Oct, 2021 US9968649
Payment of Maintenance Fee, 4th Year, Large Entity 14 Oct, 2021 US9974827
Payment of Maintenance Fee, 4th Year, Large Entity 14 Oct, 2021 US9981006
Payment of Maintenance Fee, 4th Year, Large Entity 14 Oct, 2021 US9962422
Payment of Maintenance Fee, 4th Year, Large Entity 09 Sep, 2021 US9937223


Vasopressin's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Vasopressin Generic API Manufacturers

Several generic applications have been filed for Vasopressin. The first generic version for Vasopressin was by Eagle Pharmaceuticals Inc and was approved on Dec 15, 2021. And the latest generic version is by Dr Reddys Laboratories Ltd and was approved on May 8, 2024.

Given below is the list of companies who have filed for Vasopressin generic, along with the locations of their manufacturing plants worldwide.


1. AMNEAL

Amneal Eu Ltd has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Amneal.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20UNITS/ML (20UNITS/ML)

solution Prescription INTRAVENOUS AP Aug 5, 2022


Manufacturing Plant Locations
New

Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.

Country City Firm Name
United States
Hauppauge Amneal Pharmaceuticals of New York, LLC
Paterson Amneal Pharmaceuticals, Llc
Piscataway Amneal Pharmaceuticals, LLC
Branchburg Amneal Pharmaceuticals, LLC
Brookhaven Amneal Pharmaceuticals of New York, LLC
Bridgewater Amneal Complex Products Research LLC
Glasgow Amneal Pharmaceuticals LLC
East Hanover Amneal Pharmaceuticals LLC
India
Matoda Amneal Pharmaceuticals Private Ltd.
Tal Bavla, Ahmedabad Amneal Pharmaceuticals Pvt. Ltd.
Ahmedabad Amneal Pharmaceuticals Private Ltd.
Hyderabad Amneal Oncology Private Limited





2. AMPHASTAR PHARMS INC

Amphastar Pharmaceuticals Inc has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Amphastar Pharms Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20UNITS/ML (20UNITS/ML)

solution Prescription INTRAVENOUS AP Jul 18, 2022





3. CIPLA

Cipla Ltd has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Cipla.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20UNITS/100ML (0.2UNITS/ML)

solution Prescription INTRAVENOUS AP Dec 6, 2023


Manufacturing Plant Locations
New

Cipla's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Cipla as present at those locations.

Country City Firm Name
India
Vasco Da Gama Cipla Limited
Kurkumbh Village, Dist. Pune Cipla, Ltd.
Raigad Cipla Limited
Bengaluru Cipla Limited
Mumbai Cipla Limited
Bangalore Cipla Ltd.
Pithampur, District Dhar Cipla Limited





4. DR REDDYS

Dr Reddys Laboratories Ltd has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Dr Reddys.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20UNITS/ML (20UNITS/ML)

solution Prescription INTRAVENOUS AP May 8, 2024





5. EAGLE PHARMS

Eagle Pharmaceuticals Inc has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Eagle Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20UNITS/ML (20UNITS/ML)

solution Prescription INTRAVENOUS AP Dec 15, 2021





6. EUGIA PHARMA

Eugia Pharma Specialities Ltd has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Eugia Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20UNITS/ML (20UNITS/ML)

solution Prescription INTRAVENOUS AP Aug 15, 2022


Manufacturing Plant Locations
New

Eugia Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Eugia Pharma as present at those locations.

Country City Firm Name
India
Medchal-Malkajgiri District EUGIA Pharma Specialities Limited
Riico Industrial Area EUGIA Pharma Specialities Limited
Pashamylaram Eugia Pharma Specialities Limited





7. FRESENIUS KABI USA

Fresenius Kabi Usa Llc has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20UNITS/ML (20UNITS/ML)

solution Prescription INTRAVENOUS AP May 26, 2023


Manufacturing Plant Locations
New

Fresenius Kabi Usa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Fresenius Kabi Usa as present at those locations.

Country City Firm Name
United States
Bensenville Fresenius Kabi USA LLC (FK USA)
Lake Zurich Fresenius Kabi USA, LLC
Skokie Fresenius Kabi USA LLC
North Andover Fresenius Kabi USA, LLC
Melrose Park Fresenius Kabi USA, LLC
Grand Island Fresenius Kabi USA, LLC
Wilson Fresenius Kabi USA, LLC
Melrose Park Fresenius Kabi USA LLC





8. GLAND

Gland Pharma Ltd has filed for 1 generic for Vasopressin. Given below are the details of the strengths of this generic introduced by Gland.

Strength Dosage Form Availability Application Pathway TE code Launch Date
20UNITS/ML (20UNITS/ML)

solution Prescription INTRAVENOUS AP Feb 9, 2024


Manufacturing Plant Locations
New

Gland's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Gland as present at those locations.

Country City Firm Name
India
Parawada, Visakhapatnam Gland Pharma Limited
Aurangabad Gland Chemical Private Limited
Hyderabad Gland Pharma Limited, Units I+II Pashamylaram Site
Visakhapatnam Gland Pharma Limited
Sriperumbudur Gland Chemical Private Limited
Malur Gland Chemicals Pvt Ltd.
Hyderabad Gland Pharma Limited